Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating cash flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -19.74%911M | 134.99%1.14B | ||||||||
Net income from continuing operations | 6.72%667M | ---- | ---- | ---- | ---- | 22.55%625M | ---- | ---- | ---- | ---- |
Operating gains losses | -67.71%134M | ---- | ---- | ---- | ---- | 571.59%415M | ---- | ---- | ---- | ---- |
Deferred tax | -31.48%37M | ---- | ---- | ---- | ---- | 254.29%54M | ---- | ---- | ---- | ---- |
Other non cash items | 69.44%-22M | ---- | ---- | ---- | ---- | -188.89%-72M | ---- | ---- | ---- | ---- |
Change in working capital | -15.93%95M | ---- | ---- | ---- | ---- | 653.33%113M | ---- | ---- | ---- | ---- |
-Change in receivables | -5.31%107M | ---- | ---- | ---- | ---- | 352.00%113M | ---- | ---- | ---- | ---- |
-Change in payables and accrued expense | ---12M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Cash from discontinued operating activities | ||||||||||
Operating cash flow | -19.74%911M | -155.40%-355M | 78.41%719M | -55.80%316M | 48.08%231M | 134.99%1.14B | 78.62%-139M | -3.59%403M | 102.55%715M | -56.91%156M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 82.76%-141M | 74.37%-645M | -213.02%-486M | -111.54%-92M | 129.24%1.08B | -212.98%-818M | -194.27%-2.52B | 215.59%430M | 168.06%797M | 217.12%472M |
Net investment purchase and sale | -50.00%28M | 55.16%-891M | -149.54%-160M | -71.10%204M | -13.71%875M | 530.77%56M | -249.62%-1.99B | 189.97%323M | 196.45%706M | 505.60%1.01B |
Net proceeds payment for loan | 51.23%-99M | -58.76%-435M | 1,825.00%138M | 595.00%99M | 0.00%99M | -697.06%-203M | -45.74%-274M | -214.29%-8M | -116.26%-20M | 7.61%99M |
Net business purchase and sale | 89.86%-60M | 511.81%777M | -2,592.86%-377M | -545.31%-413M | 92.67%-47M | -183.62%-592M | -92.80%127M | 90.97%-14M | 90.00%-64M | -146.54%-641M |
Net other investing changes | 87.34%-10M | 74.93%-96M | -167.44%-87M | --18M | --155M | -1,480.00%-79M | -64.38%-383M | -4.44%129M | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 82.76%-141M | 74.37%-645M | -213.02%-486M | -111.54%-92M | 129.24%1.08B | -212.98%-818M | -194.27%-2.52B | 215.59%430M | 168.06%797M | 217.12%472M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -137.19%-759M | -78.71%584M | 110.43%132M | 77.71%-220M | -54.75%-1.26B | 73.33%-320M | 299.49%2.74B | -743.33%-1.27B | -234.84%-987M | -99.26%-811M |
Net issuance payments of debt | -50.19%128M | -160.11%-339M | 294.95%425M | 114.19%21M | -64.41%21M | 185.38%257M | 178.22%564M | -1,353.33%-218M | -159.68%-148M | -68.45%59M |
Net common stock issuance | -71.82%-634M | 23.57%-120M | -238.00%-169M | -8.64%-176M | ---169M | 50.34%-369M | ---157M | -1,100.00%-50M | 35.20%-162M | --0 |
Cash dividends paid | -29.81%-209M | 0.00%-44M | -7.14%-60M | -74.07%-47M | -70.59%-58M | -38.79%-161M | -109.52%-44M | -55.56%-56M | -12.50%-27M | 2.86%-34M |
Net other financing charges | 6.38%-44M | -54.33%1.09B | 93.20%-64M | 97.23%-18M | -25.48%-1.05B | -17.50%-47M | 475.99%2.38B | -804.81%-941M | -185.75%-650M | -1,270.49%-836M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -137.19%-759M | -78.71%584M | 110.43%132M | 77.71%-220M | -54.75%-1.26B | 73.33%-320M | 299.49%2.74B | -743.33%-1.27B | -234.84%-987M | -99.26%-811M |
Net cash flow | ||||||||||
Beginning cash position | -1.44%206M | 68.48%1.55B | -12.53%1.18B | 42.72%1.18B | 11.02%1.12B | 3.47%209M | -1.93%917M | 29.84%1.35B | -26.76%824M | -35.98%1.01B |
Current changes in cash | 466.67%11M | -578.16%-416M | 184.49%365M | -99.24%4M | 131.69%58M | -142.86%-3M | -86.51%87M | -315.38%-432M | 710.47%525M | 59.15%-183M |
End cash position | 5.34%217M | 5.34%217M | 68.48%1.55B | -12.53%1.18B | 42.72%1.18B | -1.44%206M | -1.44%206M | -1.93%917M | 29.84%1.35B | -26.76%824M |
Free cash flow | -19.74%911M | -155.40%-355M | 78.41%719M | -55.80%316M | 48.08%231M | 134.99%1.14B | 78.62%-139M | -3.59%403M | 102.55%715M | -56.91%156M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |